Drug Trial Radar · NCT04430283
Evaluation of FDY-5301 in Major Trauma Patients in ICU
Last checked: Nov 19, 2026Latest source record: Jun 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Sep 20, 2021
Primary completion
Mar 4, 2022
Study completion Mar 4, 2022
Sponsor
- Lead sponsor
- Faraday Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)
Conditions
- ICU Acquired Weakness
Interventions
FDY-5301Drug
FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
PlaceboOther
Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Chelsea Critical Care Physical Assessment ToolTime frame: Day 10 or hospital discharge, whichever occurs first.
- Organ Dysfunction Total Time to RecoveryTime frame: Day 28 or hospital discharge, whichever occurs first.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Harbor-UCLA Medical Center
Torrance, California
University of Florida Health Shands Hospital
Gainesville, Florida
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts
The Ohio State University Wexner Medical Center
Columbus, Ohio
Harborview
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.